PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q92149

Tomoyuki HASEGAWA, et al.

Appln. No.: National Stage Entry of PCT/JP2004/009263

Confirmation No.: Unknown Group Art Unit: Unknown

Filed: December 19, 2005 Examiner: Unknown

For: METHANESULFONIC ACID SALT OF PYRAZOLOPYRIMIDINE COMPOUND,

CRYSTAL THEREOF, AND PROCESS FOR PRODUCING THE SAME

## <u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. §§ 1.97 and 1.98</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/561214

IAPO REC'OPCTAPTO 19 DEC 2009

INFORMATION DISCLOSURE STATEMENT National Stage Entry of PCT/JP2004/009263

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents (International Search

Report for PCT/JP2004/009263 dated September 21, 2004), together with an English-language

version (if not already included) of at least that portion of the Communication indicating the

degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Registration No. 32,197

Mark Boland

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

**WASHINGTON OFFICE** 

23373

**CUSTOMER NUMBER** 

Date: December 19, 2005

2

MODIFIED PTO/SB/08 A & B (06-03)

Substitute for Form 1449 A & B/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Application Number	PCT/JP2004/009263			
Confirmation Number				
<del></del>	Unknown			
Filing Date	December 19, 2005			
First Named Inventor	Tomoyuki HASEGAWA			
Art Unit	Unknown			
 Examiner Name	Unknown			
Attorney Docket Number	Q92149			

U.S. PATENT DOCUMENTS						
		Document Number				
Examiner Initials*	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
·		US				
		US				
		US				
		US				
		US				
		US				
	-	US				
	" · ·	US				
		US				

			F	OREIGN PA	TENT DOCUM	ENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation <sup>6</sup>
		JР	5-112571	A	05-07-1993	OTSUKA PHARMACEUTICAL CO., LTD.	Abstract
		wo	02/053565	A1	07-11-2002	ONO PHARMACEUTICAL CO., LTD.	Abstract
		wo	97/11946	A1	04-03-1997	OTSUKA PHARMACEUTICAL CO., LTD.	Abstract
						·	_
				<u> </u>			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
		International Search Report dated September 21, 2004			
	<del></del>				
	<del> </del>		· · · · · · · · · · · · · · · · · · ·		
	<del></del>				

Examiner Signature		Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.